The estimated Net Worth of Vincent Aurentz is at least $6.85 Million dollars as of 16 February 2021. Mr. Aurentz owns over 2,524 units of Arena Pharmaceuticals Inc stock worth over $2,952,105 and over the last 8 years he sold ARNA stock worth over $450,000. In addition, he makes $3,449,400 as Executive Vice President and Chief Business Officer at Arena Pharmaceuticals Inc.
Sign up
Mr. Aurentz ARNA stock SEC Form 4 insiders trading
Vincent has made over 7 trades of the Arena Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 2,524 units of ARNA stock worth $37,355 on 16 February 2021.
The largest trade he's ever made was exercising 65,000 units of Arena Pharmaceuticals Inc stock on 9 September 2019 worth over $1,641,250. On average, Vincent trades about 9,168 units every 35 days since 2016. As of 16 February 2021 he still owns at least 29,524 units of Arena Pharmaceuticals Inc stock.
You can see the complete history of Mr. Aurentz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vincent Aurentz biography
Vincent E. Aurentz serves as Executive Vice President and Chief Business Officer of the Company. Mr. Aurentz has served as our Executive Vice President and Chief Business Officer since August 2016. Mr. Aurentz has almost 30 years of experience in the biopharmaceutical industry. Previously, he was the Chief Business Officer of Epirus Biopharmaceuticals, Inc. from November 2015 to July 2016. Prior to that, Mr. Aurentz served as President and was a member of the Board of Directors of HemoShear Therapeutics, LLC from July 2013 to November 2015, where he oversaw the scientific platform, R&D activities, commercial and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly, Janssen R&D and Children’s National Health System. Prior to joining HemoShear, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono S.A.) where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments. Mr. Aurentz is a former Executive Vice President at Quintiles and a Co-founder and Managing Director of a venture capital and advisory business. He was a partner with CSC Healthcare, the life sciences strategic management consulting division of Computer Sciences Corporation, after starting his career and working for 8 years at Andersen Consulting (now Accenture). In July 2016, Epirus filed a voluntary Chapter 7 petition in the United States Bankruptcy Court for the District of Massachusetts. Mr. Aurentz received a B.S. in mathematics from Villanova University.
What is the salary of Vincent Aurentz?
As the Executive Vice President and Chief Business Officer of Arena Pharmaceuticals Inc, the total compensation of Vincent Aurentz at Arena Pharmaceuticals Inc is $3,449,400. There are 1 executives at Arena Pharmaceuticals Inc getting paid more, with Amit Munshi having the highest compensation of $8,931,400.
How old is Vincent Aurentz?
Vincent Aurentz is 52, he's been the Executive Vice President and Chief Business Officer of Arena Pharmaceuticals Inc since 2016. There are 11 older and 2 younger executives at Arena Pharmaceuticals Inc. The oldest executive at Arena Pharmaceuticals Inc is Garry Neil, 67, who is the Independent Director.
What's Vincent Aurentz's mailing address?
Vincent's mailing address filed with the SEC is C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO, CA, 92121.
Insiders trading at Arena Pharmaceuticals Inc
Over the last 21 years, insiders at Arena Pharmaceuticals Inc have traded over $9,243,184 worth of Arena Pharmaceuticals Inc stock and bought 78,040 units worth $252,505 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Manmeet Singh Soni, and Garry Arthur Neil. On average, Arena Pharmaceuticals Inc executives and independent directors trade stock every 39 days with the average trade being worth of $3,133,387. The most recent stock trade was executed by Amit Munshi on 16 August 2021, trading 1,000 units of ARNA stock currently worth $48,190.
What does Arena Pharmaceuticals Inc do?
Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas
What does Arena Pharmaceuticals Inc's logo look like?
Complete history of Mr. Aurentz stock trades at Arena Pharmaceuticals Inc
Arena Pharmaceuticals Inc executives and stock owners
Arena Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Amit Munshi,
Director, President and Chief Executive Officer -
Vincent Aurentz,
Executive Vice President and Chief Business Officer -
Robert Lisicki,
Executive Vice President and Chief Commercial Officer -
Amit D. Munshi M.B.A.,
Pres, CEO & Director -
Vincent E. Aurentz,
Exec. VP & Chief Bus. Officer -
Dr. Christopher H. Cabell FACC, M.D., MHS,
Advisor -
Laurie D. Stelzer,
Exec. VP & CFO -
Joan Schmidt,
Exec. VP, Gen. Counsel & Sec. -
Tina Nova,
Independent Chairman of the Board -
Jennifer Jarrett,
Independent Director -
Randall Woods,
Independent Director -
Jayson Dallas,
Independent Director -
Manmeet Soni,
Independent Director -
Kieran Gallahue,
Independent Director -
Oliver Fetzer,
Independent Director -
Garry Neil,
Independent Director -
Katharine Knobil,
Director -
Joan Schmidt,
Executive Vice President, General Counsel, Secretary -
Laurie Stelzer,
Chief Financial Officer, Executive Vice President -
Patrick Malloy,
VP of Investor Relations & Corp. Communications -
Megan E. Knight,
Director of Investor Relations -
Dr. Lamine Mbow Ph.D.,
Sr. VP & Chief Scientific Officer -
Dr. Douglas A. Bakan Ph.D.,
Exec. VP of Technical Operations -
Harry F Jr Hixson,
Director -
Maurice James Mezzino,
SVP, Corporate Development -
Phillip M Schneider,
Director -
Preston Klassen,
EVP and CMO -
Steven W Spector,
EVP, General Counsel & Sec -
Scott H Bice,
Director -
Kevin Robert Lind,
Executive VP and CFO -
Christine Anna White,
Director -
Donald D Belcher,
Director -
Nawal Ouzren,
Director -
Frederick Frank,
-
Mark N Lampert,
Director -
Robert Hoffman,
SVP, Finance and CFO -
Partners L P/Ilbiotechnolog...,
-
James Laforce,
Director -
Jennifer Kathleen Bielasz,
VP, Accounting & Controller -
K A Ajit Simh,
VP, Quality Systems -
Jack Lief,
Chairman, President and CEO -
Craig Michael Audet,
SVP, Opn & Head Glob Reg Afrs -
Duke K Bristow,
Director -
Robert L Toms,
Director -
Paul W Maffuid,
VP, Pharmaceutical Development -
Joyce H Williams,
VP, Drug Development -
Partners L P/Ilbvf Inc/Ilbi...,
-
Nigel R A Beeley,
VP, Chief Chemical Officer -
Joseph F Mooney,
Chief Financial Officer -
Derek T Chalmers,
Vice President, Research -
Louis J Scotti,
VP, Marketing and Bus Dev -
Dominic P Behan,
EVP & Chief Scientific Officer -
James Edeerfield Capital Lp...,
-
Louis J Jr Lavigne,
Director -
William R Jr Shanahan,
SVP & Chief Medical Officer -
Christopher Cabell,
EVP, Head of R&D, and CMO -
Steven J Schoch,
Director -
Douglas J. Manion,
EVP Research & Development